The pre-treatment and EOT biochemical studies showed that IFN-free DAA administration significantly normalized AST and ALT, regardless of whether patients developed early-emerging HCC or not (S3B Fig). This evidence concerns the gene IFNA1 and hepatocellular carcinoma.